- FDA approves Tivicay pd for youngest HIV patients
- Koala trial doses first patient with novel KMA‑targeting CAR‑T
- Heparegenix wins orphan drug status for darizmetinib
- IMAVVY approved as first targeted therapy for wAIHA
- Nxera partner gains acceptance for NBI‑1117567
- Jemperli accepted for priority review by US FDA
- Carterra supports AI‑designed protein study with HT-SPR platforms
- Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
- Avulux gains FDA authorisation for migraine light‑sensitivity lens
- Leqembi Iqlik launches in US for early Alzheimer’s
- Lundbeck gains EU orphan status for anti‑ACTH antibody
- AC Immune reports positive phase 1 data for ACI‑19764
- VarmX begins global phase 3 trial of VMX C001
- VarmX begins global phase 3 trial for VMX C001
- FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough
- MHRA sets out position on microbiome‑based medicinal products
- US FDA accepts Teva’s new drug application for ecopipam
- NICE backs Axhidrox for severe underarm sweating
- Alzecure completes transaction with Lilly
- EffRx to commercialise Testavan in Switzerland
Website: https://www.pharmatimes.com
